Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Steven Coutre*, Alessandra Tedeschi, Tadeusz Robak, Paul M. Barr, Carolyn Owen, Osnat Bairey, Jan Burger, Cathy Zhou, Lori Styles, Danelle F. James, Thomas J. Kipps

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e249-e251
JournalHaematologica
Volume103
Issue number6
DOIs
StatePublished - 3 Jun 2018

Funding

FundersFunder number
National Cancer InstituteP30CA016672
AbbVie
Pharmacyclics

    Cite this